Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension
- PMID: 33706870
- PMCID: PMC7959178
- DOI: 10.1016/j.jacc.2021.01.014
Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension
Abstract
Background: Standard blood pressure control metrics may not account for fluctuations in blood pressure over time.
Objectives: This study sought to estimate the independent association between time in systolic blood pressure target range and major adverse cardiovascular events among adults with hypertension.
Methods: This study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a randomized clinical trial that compared intensive (<120 mm Hg) and standard (<140 mm Hg) systolic blood pressure treatment interventions in adults with hypertension and high cardiovascular risk. Target range was defined as 110 to 130 mm Hg and 120 to 140 mm Hg for the intensive and standard arms, respectively. Time in target range was estimated over the first 3 months of follow-up using linear interpolation. The association between time in target range with major adverse cardiovascular events was estimated using adjusted Cox proportional hazards regression models.
Results: Participants with greater time in target range were younger, had lower 10-year cardiovascular risk and lower baseline systolic blood pressure, and were more likely women and statin users. Each 1-SD increase in time in target range was significantly associated with a decreased risk of first major adverse cardiovascular event in fully adjusted models. Time in target range remained significantly associated with major adverse cardiovascular events despite adjustment for mean systolic blood pressure or systolic blood pressure variability. Among participants with mean systolic blood pressure at or below target, time in target range remained associated with major adverse cardiovascular events.
Conclusions: Time in systolic blood pressure target range independently predicts major adverse cardiovascular event risk.
Keywords: hypertension; quality of care; time in target range.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures
Comment in
-
Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control.J Am Coll Cardiol. 2021 Mar 16;77(10):1300-1301. doi: 10.1016/j.jacc.2021.01.019. J Am Coll Cardiol. 2021. PMID: 33706871 Free PMC article. No abstract available.
Similar articles
-
Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.JAMA Netw Open. 2019 Mar 1;2(3):e190005. doi: 10.1001/jamanetworkopen.2019.0005. JAMA Netw Open. 2019. PMID: 30848803 Free PMC article. Clinical Trial.
-
Incremental effects of antihypertensive drugs: instrumental variable analysis.BMJ. 2017 Dec 22;359:j5542. doi: 10.1136/bmj.j5542. BMJ. 2017. PMID: 29273586 Free PMC article.
-
Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.Am J Med. 2018 Oct;131(10):1228-1233.e1. doi: 10.1016/j.amjmed.2018.05.022. Epub 2018 Jun 12. Am J Med. 2018. PMID: 29906425 Clinical Trial.
-
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3. Epub 2015 Nov 7. Lancet. 2016. PMID: 26559744 Review.
-
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei Med J. 2016 Nov;57(6):1307-11. doi: 10.3349/ymj.2016.57.6.1307. Yonsei Med J. 2016. PMID: 27593856 Free PMC article. Review.
Cited by
-
Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials.Hypertens Res. 2024 Nov 14. doi: 10.1038/s41440-024-01949-4. Online ahead of print. Hypertens Res. 2024. PMID: 39543413 Review.
-
Association Between Systolic Blood Pressure Time in Target Range Indices and Adverse Cardiovascular Outcomes.JACC Adv. 2024 Oct 18;3(11):101350. doi: 10.1016/j.jacadv.2024.101350. eCollection 2024 Nov. JACC Adv. 2024. PMID: 39497947 Free PMC article.
-
Time in target range for systolic blood pressure and glucose with cardiovascular disease and all-cause mortality risks.Hypertens Res. 2024 Oct 30. doi: 10.1038/s41440-024-01969-0. Online ahead of print. Hypertens Res. 2024. PMID: 39478190
-
Home blood pressure stability score is associated with better cardiovascular prognosis: data from the nationwide prospective J-HOP study.Hypertens Res. 2024 Oct 12. doi: 10.1038/s41440-024-01940-z. Online ahead of print. Hypertens Res. 2024. PMID: 39394518
-
The association of out-of-office blood pressure time in target range with clinical outcomes.Hypertens Res. 2024 Sep 27. doi: 10.1038/s41440-024-01918-x. Online ahead of print. Hypertens Res. 2024. PMID: 39333664 No abstract available.
References
-
- Quality ID #236 (NQF 0018): Controlling High Blood Pressure. 2020.
-
- Wang J, Shi X, Ma C et al. Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2017;35:10–17. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
